MX2013011199A - Metodos para tratar el cancer. - Google Patents

Metodos para tratar el cancer.

Info

Publication number
MX2013011199A
MX2013011199A MX2013011199A MX2013011199A MX2013011199A MX 2013011199 A MX2013011199 A MX 2013011199A MX 2013011199 A MX2013011199 A MX 2013011199A MX 2013011199 A MX2013011199 A MX 2013011199A MX 2013011199 A MX2013011199 A MX 2013011199A
Authority
MX
Mexico
Prior art keywords
treating cancer
methods
hdr
inhibits
regulates
Prior art date
Application number
MX2013011199A
Other languages
English (en)
Inventor
Charles Hart
Mark Matteucci
John Curd
Original Assignee
Threshold Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Threshold Pharmaceuticals Inc filed Critical Threshold Pharmaceuticals Inc
Publication of MX2013011199A publication Critical patent/MX2013011199A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe que la administración de TH-302 u otro profármaco activado por la hipoxia en combinación con un agente farmacológico que sub-regula o inhibe la reparación dirigida por homología (HDR) es útil para el tratamiento de cáncer.
MX2013011199A 2011-04-01 2012-03-30 Metodos para tratar el cancer. MX2013011199A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161470921P 2011-04-01 2011-04-01
PCT/US2012/031677 WO2012135757A2 (en) 2011-04-01 2012-03-30 Methods for treating cancer

Publications (1)

Publication Number Publication Date
MX2013011199A true MX2013011199A (es) 2013-12-16

Family

ID=46932420

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011199A MX2013011199A (es) 2011-04-01 2012-03-30 Metodos para tratar el cancer.

Country Status (12)

Country Link
US (1) US20140171389A1 (es)
EP (1) EP2694062A4 (es)
JP (1) JP2014509658A (es)
KR (1) KR20140038390A (es)
CN (1) CN103458896B (es)
AU (1) AU2012236142A1 (es)
BR (1) BR112013024730A2 (es)
CA (1) CA2831612A1 (es)
IL (1) IL228644A0 (es)
MX (1) MX2013011199A (es)
RU (1) RU2013146659A (es)
WO (1) WO2012135757A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006263433B8 (en) 2005-06-29 2011-06-09 Immunogenesis, Inc. Phosphoramidate alkylator prodrugs
WO2013096687A1 (en) 2011-12-22 2013-06-27 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer
WO2013126539A1 (en) * 2012-02-21 2013-08-29 Threshold Pharmaceuticals Inc. Treatment of cancer
WO2015013448A1 (en) 2013-07-26 2015-01-29 Threshold Pharmaceuticals, Inc. Treatment of pancreatic cancer with a combination of a hypoxia-acti vated prodrug and a taxane
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
CN110680824A (zh) * 2018-07-05 2020-01-14 深圳艾欣达伟医药科技有限公司 埃夫索胺的抗癌医药用途
US20220249522A1 (en) * 2018-12-07 2022-08-11 The Board Of Trustees Of The Leland Stanford Junior University Hypoxia Targeting Compositions and Combinations Thereof with a PARP Inhibitor and Methods of Use Thereof
CN117651548A (zh) 2021-08-27 2024-03-05 深圳艾欣达伟医药科技有限公司 冻干制剂溶液及冻干制剂、方法和用途
WO2023025312A1 (zh) 2021-08-27 2023-03-02 深圳艾欣达伟医药科技有限公司 使用th-302治疗parp抑制剂耐药的患者
WO2023198188A1 (zh) * 2022-04-15 2023-10-19 深圳艾欣达伟医药科技有限公司 使用th-302单药或联用parp抑制剂治疗癌症的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005288736B2 (en) * 2004-09-27 2008-08-14 Astrazeneca Ab Cancer combination therapy comprising AZD2171 and imatinib
AU2006263433B8 (en) 2005-06-29 2011-06-09 Immunogenesis, Inc. Phosphoramidate alkylator prodrugs
ES2884044T3 (es) * 2006-12-26 2021-12-10 Immunogenesis Inc Profármaco alquilante de fosforamidato para el tratamiento del cáncer
CN101616671A (zh) * 2007-01-19 2009-12-30 卫材R&D管理有限公司 胰腺癌治疗用组合物
ES2884674T3 (es) * 2008-10-21 2021-12-10 Immunogenesis Inc Tratamiento del cáncer con el profármaco activado por hipoxia TH-302 en combinación con docetaxel o pemetrexed
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
RU2013102398A (ru) * 2010-06-28 2014-08-10 Тресхолд Фармасьютикалз, Инк. Лечение рака крови
ES2649340T3 (es) 2010-07-12 2018-01-11 Threshold Pharmaceuticals, Inc. Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer

Also Published As

Publication number Publication date
CN103458896B (zh) 2016-02-10
EP2694062A4 (en) 2014-11-12
EP2694062A2 (en) 2014-02-12
CA2831612A1 (en) 2012-10-04
US20140171389A1 (en) 2014-06-19
KR20140038390A (ko) 2014-03-28
WO2012135757A3 (en) 2012-11-29
RU2013146659A (ru) 2015-05-10
JP2014509658A (ja) 2014-04-21
AU2012236142A1 (en) 2013-10-17
BR112013024730A2 (pt) 2016-12-20
CN103458896A (zh) 2013-12-18
IL228644A0 (en) 2013-12-31
WO2012135757A2 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
MX2013011199A (es) Metodos para tratar el cancer.
IL276414A (en) A pyruvate kinase activator for therapeutic use
HK1254083A1 (zh) 用於治療癌症的缺氧活化前驅藥物和抗血管生成劑
HK1192758A1 (zh) '- 用於治療癌症的 -氟- '-脱氧尿苷的氨基磷酸酯衍生物
MX2016004678A (es) Composiciones para el tratamiento del cancer.
MX2011008221A (es) Tratamiento de cancer de pulmon con un compuesto de nitrobenzamida en combinacion con un inhibidor de un factor de crecimieno.
MY161237A (en) Combination therapy comprising a cdk4/6 inhibitor and a p13k inhibitor for use in the treatment of cancer
EP2714081A4 (en) METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
MX2015014431A (es) Monoterapia con glucopiranosil lipido a para usarse en el tratamieto del cancer.
PH12014502048B1 (en) Treatment of cancer with tor kinase inhibitors
EP2957657A4 (en) ONE-SIDED ELECTRO-GALVANIZED CHROMATE SURFACE TREATMENT FOR STEEL PLATE FOR FUEL TANK AND SURFACE TREATMENT AGENT
HK1198133A1 (en) Crizotinib for use in the treatment of cancer
PH12014502046A1 (en) Treatment of cancer with tor kinase inhibitors
EP2793882A4 (en) ADMINISTRATION OF HYPOXIA ACTIVATED DRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER
IL239007B (en) Eribulin for use in the treatment of breast cancer
HK1199875A1 (en) Morpholinyl benzotriazine for use in cancer therapy
CA144275S (en) Front combination lamp for automobiles
MX2013011932A (es) Inhibidores de parp para el tratamiento de cipn.
EP2836217A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SIDE EFFECTS ASSOCIATED WITH THE ADMINISTRATION OF ANTICANCER CHEMOTHERAPEUTIC AGENTS
NZ631749A (en) Methods of treating cancer using angiogenin or an angiogenin agonist
MX2013011623A (es) Regimenes de tratamiento.
MX2011008069A (es) Uso de inhibidores de topoisomerasa i para tratar el cancer.
MX2015007054A (es) Combinaciones de un compuesto inhibidor de pi3k/akt con un compuesto inhibidor de her3/egfr, y métodos de uso.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal